» Articles » PMID: 28490466

RET Signaling in Prostate Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2017 May 12
PMID 28490466
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Large diameter perineural prostate cancer is associated with poor outcomes. GDNF, with its coreceptor GFRα1, binds RET and activates downstream pro-oncogenic signaling. Because both GDNF and GFRα1 are secreted by nerves, we examined the role of RET signaling in prostate cancer. Expression of RET, GDNF, and/or GFRα1 was assessed. The impact of RET signaling on proliferation, invasion and soft agar colony formation, perineural invasion, and growth was determined. Cellular signaling downstream of RET was examined by Western blotting. RET is expressed in all prostate cancer cell lines. GFRα1 is only expressed in 22Rv1 cells, which is the only line that responds to exogenous GDNF. In contrast, all cell lines respond to GDNF plus GFRα1. Conditioned medium from dorsal root ganglia contains secreted GFRα1 and promotes transformation-related phenotypes, which can be blocked by anti-GFRα1 antibody. Perineural invasion in the dorsal root ganglion assay is inhibited by anti-GFRα antibody and RET knockdown. , knockdown of RET inhibits tumor growth. RET signaling activates ERK or AKT signaling depending on context, but phosphorylation of p70S6 kinase is markedly increased in all cases. Knockdown of p70S6 kinase markedly decreases RET induced transformed phenotypes. Finally, RET is expressed in 18% of adenocarcinomas and all three small-cell carcinomas examined. RET promotes transformation associated phenotypes, including perineural invasion in prostate cancer via activation of p70S6 kinase. GFRα1, which is secreted by nerves, is a limiting factor for RET signaling, creating a perineural niche where RET signaling can occur. .

Citing Articles

Investigating the Potential Effects of 6PPDQ on Prostate Cancer Through Network Toxicology and Molecular Docking.

Song Y, Weng W, Wu S Toxics. 2025; 12(12.

PMID: 39771106 PMC: 11728691. DOI: 10.3390/toxics12120891.


Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.

Huai J, Wang F, Zhang W, Lou Y, Wang G, Huang L Front Endocrinol (Lausanne). 2024; 15:1484815.

PMID: 39439561 PMC: 11493660. DOI: 10.3389/fendo.2024.1484815.


Identification of anoikis-related gene signatures and construction of the prognosis model in prostate cancer.

Kang W, Ye C, Yang Y, Lou Y, Zhao M, Wang Z Front Pharmacol. 2024; 15:1383304.

PMID: 38957390 PMC: 11217483. DOI: 10.3389/fphar.2024.1383304.


The contribution of the nervous system in the cancer progression.

Park H, Lee C BMB Rep. 2024; 57(4):167-175.

PMID: 38523371 PMC: 11058356.


Role of adenosine deaminase in prostate cancer progression.

Charles C, Lloyd S, Piyarathna D, Gohlke J, Rasaily U, Putluri V Am J Clin Exp Urol. 2023; 11(6):594-612.

PMID: 38148936 PMC: 10749386.


References
1.
Ayala G, Dai H, Powell M, Li R, Ding Y, Wheeler T . Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008; 14(23):7593-603. DOI: 10.1158/1078-0432.CCR-08-1164. View

2.
Drake J, Graham N, Stoyanova T, Sedghi A, Goldstein A, Cai H . Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A. 2012; 109(5):1643-8. PMC: 3277127. DOI: 10.1073/pnas.1120985109. View

3.
Robinson D, He F, Pretlow T, Kung H . A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci U S A. 1996; 93(12):5958-62. PMC: 39170. DOI: 10.1073/pnas.93.12.5958. View

4.
Dakhova O, Ozen M, Creighton C, Li R, Ayala G, Rowley D . Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009; 15(12):3979-89. PMC: 2734921. DOI: 10.1158/1078-0432.CCR-08-1899. View

5.
Borromeo M, Savage T, Kollipara R, He M, Augustyn A, Osborne J . ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. Cell Rep. 2016; 16(5):1259-1272. PMC: 4972690. DOI: 10.1016/j.celrep.2016.06.081. View